메뉴 건너뛰기




Volumn 25, Issue 6, 2009, Pages 1445-1454

Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis

Author keywords

Budget impact; Cost effectiveness; Disease modifying therapy; Multiple sclerosis; Natalizumab

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB;

EID: 67649448986     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902876040     Document Type: Article
Times cited : (32)

References (34)
  • 1
    • 0028157044 scopus 로고
    • Pathogenesis of multiple sclerosis
    • ffrench-Constant C. Pathogenesis of multiple sclerosis. Lancet 1994;343:271-275
    • (1994) Lancet , vol.343 , pp. 271-275
    • Ffrench-Constant, C.1
  • 2
    • 67649430621 scopus 로고    scopus 로고
    • Accessed December 19, 2008
    • National MS Society Information Sourcebook: Epidemiology. National Multiple Sclerosis Society Web site. http://main.nationalmssociety.org/docs/HOM/ epidemiology.pdf. Accessed December 19, 2008
    • National MS Society Information Sourcebook: Epidemiology
  • 7
    • 0027418515 scopus 로고
    • Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
    • The IFNB Multiple Sclerosis Study Group
    • The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661
    • (1993) Neurology , Issue.43 , pp. 655-661
  • 8
    • 0029082566 scopus 로고
    • Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial
    • The Copolymer Multiple Sclerosis Study Group
    • Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer Multiple Sclerosis Study Group. Neurology 1995;45:1268-1276
    • (1995) Neurology , vol.45 , pp. 1268-1276
    • Johnson, K.P.1    Brooks, B.R.2    Cohen, J.A.3
  • 10
    • 0345601517 scopus 로고    scopus 로고
    • Randomised double-blind placebo-controlled study of interferon beta-in relapsing/remitting multiple sclerosis
    • PRISMS (Prevention of Relapses and Disability by Interferon beta-Subcutaneously in Multiple Sclerosis) Study Group
    • PRISMS (Prevention of Relapses and Disability by Interferon beta-Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504
    • (1998) Lancet , vol.352 , pp. 1498-1504
  • 14
    • 46849108700 scopus 로고    scopus 로고
    • Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden
    • DOI 10.1177/1352458507086667
    • Kobelt G, Berg J, Lindgren P, et al. Modeling the cost effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden. Mult Scler 2008;14:679-690 (Pubitemid 351954411)
    • (2008) Multiple Sclerosis , vol.14 , Issue.5 , pp. 679-690
    • Kobelt, G.1    Berg, J.2    Lindgren, P.3    Jonsson, B.4    Stawiarz, L.5    Hillert, J.6
  • 15
    • 45849092934 scopus 로고    scopus 로고
    • Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK
    • DOI 10.2165/00019053-200826070-00008
    • Gani R, Giovannoni G, Bates D, et al. Cost effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics 2008;26:617-627 (Pubitemid 351876727)
    • (2008) PharmacoEconomics , vol.26 , Issue.7 , pp. 617-627
    • Gani, R.1    Giovannoni, G.2    Bates, D.3    Kemball, B.4    Hughes, S.5    Kerrigan, J.6
  • 17
    • 35748930835 scopus 로고    scopus 로고
    • Issued January Accessed December 19, 2008
    • Multiple sclerosis - beta interferon and glatiramer acetate. National Institute for Health and Clinical Excellence (NICE) Web site. http://www.nice.org.uk/Guidance/TA32. Issued January 2002. Accessed December 19, 2008
    • (2002) Multiple Sclerosis - Beta Interferon and Glatiramer Acetate
  • 21
    • 0028140558 scopus 로고    scopus 로고
    • Impairment, disability, and handicap in multiple sclerosis: A population-based study in Olmsted County, Minnesota
    • Rodriguez M, Siva A, Ward J, et al. Impairment, disability, and handicap in multiple sclerosis: A population-based study in Olmsted County, Minnesota. Neurology 2004;44:28-33
    • (2004) Neurology , vol.44 , pp. 28-33
    • Rodriguez, M.1    Siva, A.2    Ward, J.3
  • 22
    • 67649455674 scopus 로고    scopus 로고
    • MAG Mutual Healthcare Solutions, Inc., Duluth, GA
    • 2008 Physicians' Fee and Coding Guide. MAG Mutual Healthcare Solutions, Inc., Duluth, GA
    • 2008 Physicians' Fee and Coding Guide
  • 24
    • 59249093995 scopus 로고    scopus 로고
    • Utilization of health care by patients with multiple sclerosis is based on professional and patient-defined health needs
    • Beckerman H, van Zee IE, de Groot V, et al. Utilization of health care by patients with multiple sclerosis is based on professional and patient-defined health needs. Mult Scler 2008;14:1269-1279
    • (2008) Mult Scler , vol.14 , pp. 1269-1279
    • Beckerman, H.1    Van Zee, I.E.2    De Groot, V.3
  • 25
    • 3042739652 scopus 로고    scopus 로고
    • 4-integrin antagonist selective adhesion molecule inhibitors for MS
    • DOI 10.1586/14737175.4.4.571
    • Rudick R, Sandrock AW. Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurotherapeutics 2004;4:571-580 (Pubitemid 38890585)
    • (2004) Expert Review of Neurotherapeutics , vol.4 , Issue.4 , pp. 571-580
    • Rudick, R.A.1    Sandrock, A.2
  • 26
    • 0034955141 scopus 로고    scopus 로고
    • Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
    • DOI 10.1002/ana.1032
    • McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127 (Pubitemid 32591472)
    • (2001) Annals of Neurology , vol.50 , Issue.1 , pp. 121-127
    • Buckley, C.1    Douek, D.2    Newsom-Davis, J.3    Vincent, A.4    Willcox, N.5
  • 27
    • 3042781524 scopus 로고    scopus 로고
    • Cost of managing an episode of relapse in multiple sclerosis in the United States
    • DOI 10.1186/1472-6963-3-1, 17
    • O'Brien JA, Ward AJ, Patrick AR, Caro J. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003;3:17-28 (Pubitemid 38865232)
    • (2003) BMC Health Services Research , vol.3 , pp. 1-12
    • O'Brien, J.A.1    Ward, A.J.2    Patrick, A.R.3    Caro, J.4
  • 28
    • 0003617159 scopus 로고    scopus 로고
    • US Bureau of Labor Statistics. Washington, DC: US Bureau of Labor Statistics; January 16, Publication USDL-03-15
    • US Bureau of Labor Statistics. Consumer Price Index: December 2002. Washington, DC: US Bureau of Labor Statistics; January 16, 2003. Publication USDL-03-15
    • (2003) Consumer Price Index: December 2002
  • 29
    • 67649448235 scopus 로고    scopus 로고
    • US Bureau of Labor Statistics. Washington, DC: US Bureau of Labor Statistics; November 16, Publication USDL-06-1979
    • US Bureau of Labor Statistics. Consumer Price Index: October 2006. Washington, DC: US Bureau of Labor Statistics; November 16, 2006. Publication USDL-06-1979
    • (2006) Consumer Price Index: October 2006
  • 30
    • 37449008267 scopus 로고    scopus 로고
    • The immunogenicity of disease-modifying therapies for multiple sclerosis: Clinical implications for neurologists
    • Fox EJ, Vartanian TK, Zamvil SS. The immunogenicity of disease-modifying therapies for multiple sclerosis: clinical implications for neurologists. Neurologist 2007;13:355-362
    • (2007) Neurologist , vol.13 , pp. 355-362
    • Fox, E.J.1    Vartanian, T.K.2    Zamvil, S.S.3
  • 32
    • 13844315516 scopus 로고    scopus 로고
    • Stopping beta-interferon therapy in multiple sclerosis: An analysis of stopping patterns
    • DOI 10.1191/1352458505ms1131oa
    • O'Rourke KET, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005;11:46-50 (Pubitemid 40259974)
    • (2005) Multiple Sclerosis , vol.11 , Issue.1 , pp. 46-50
    • O'Rourke, K.E.T.1    Hutchinson, M.2
  • 34
    • 67649297820 scopus 로고    scopus 로고
    • Quantitative riskbenefit analysis of natalizumab
    • Thompson JP, Noyes K, Dorsey ER, et al. Quantitative riskbenefit analysis of natalizumab. Neurology 2008;71:357-364
    • (2008) Neurology , vol.71 , pp. 357-364
    • Thompson, J.P.1    Noyes, K.2    Dorsey, E.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.